company background image
AFT

AFT PharmaceuticalsNZSE:AFT Stock Report

Last Price

NZ$4.03

Market Cap

NZ$436.6m

7D

-7.4%

1Y

-22.6%

Updated

24 Jan, 2022

Data

Company Financials +
AFT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance6/6
Financial Health5/6
Dividends0/6

AFT Stock Overview

AFT Pharmaceuticals Limited develops, licenses, distributes, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for AFT Pharmaceuticals
Historical stock prices
Current Share PriceNZ$4.03
52 Week HighNZ$5.24
52 Week LowNZ$4.00
Beta0.099
1 Month Change-7.99%
3 Month Change-1.47%
1 Year Change-22.65%
3 Year Change87.44%
5 Year Change52.08%
Change since IPO30.00%

Recent News & Updates

Dec 01
Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

How far off is AFT Pharmaceuticals Limited ( NZSE:AFT ) from its intrinsic value? Using the most recent financial data...

Shareholder Returns

AFTNZ PharmaceuticalsNZ Market
7D-7.4%-1.5%-3.2%
1Y-22.6%-15.2%-11.4%

Return vs Industry: AFT underperformed the NZ Pharmaceuticals industry which returned -15.2% over the past year.

Return vs Market: AFT underperformed the NZ Market which returned -11.4% over the past year.

Price Volatility

Is AFT's price volatile compared to industry and market?
AFT volatility
AFT Average Weekly Movement4.4%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement3.8%
10% most volatile stocks in NZ Market6.5%
10% least volatile stocks in NZ Market2.4%

Stable Share Price: AFT is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: AFT's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199794Hartley Atkinsonhttps://www.aftpharm.com

AFT Pharmaceuticals Limited develops, licenses, distributes, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally. The company offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail and oral care, pain management, skin care, and other products, as well as supplements. The company was incorporated in 1997 and is headquartered in Auckland, New Zealand.

AFT Pharmaceuticals Fundamentals Summary

How do AFT Pharmaceuticals's earnings and revenue compare to its market cap?
AFT fundamental statistics
Market CapNZ$436.59m
Earnings (TTM)NZ$10.65m
Revenue (TTM)NZ$119.80m

39.6x

P/E Ratio

3.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AFT income statement (TTM)
RevenueNZ$119.80m
Cost of RevenueNZ$64.68m
Gross ProfitNZ$55.11m
ExpensesNZ$44.47m
EarningsNZ$10.65m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.10
Gross Margin46.01%
Net Profit Margin8.89%
Debt/Equity Ratio93.7%

How did AFT perform over the long term?

See historical performance and comparison

Valuation

Is AFT Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AFT (NZ$4.03) is trading below our estimate of fair value (NZ$8.83)

Significantly Below Fair Value: AFT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AFT is poor value based on its PE Ratio (39.6x) compared to the Oceanic Pharmaceuticals industry average (24.8x).

PE vs Market: AFT is poor value based on its PE Ratio (39.6x) compared to the NZ market (18.8x).


Price to Earnings Growth Ratio

PEG Ratio: AFT is poor value based on its PEG Ratio (1.1x)


Price to Book Ratio

PB vs Industry: AFT is overvalued based on its PB Ratio (10.3x) compared to the XO Pharmaceuticals industry average (3.2x).


Future Growth

How is AFT Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

37.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AFT's forecast earnings growth (37.6% per year) is above the savings rate (2.1%).

Earnings vs Market: AFT's earnings (37.6% per year) are forecast to grow faster than the NZ market (7.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AFT's revenue (22% per year) is forecast to grow faster than the NZ market (4.8% per year).

High Growth Revenue: AFT's revenue (22% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AFT's Return on Equity is forecast to be high in 3 years time (27.5%)


Past Performance

How has AFT Pharmaceuticals performed over the past 5 years?

64.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AFT has high quality earnings.

Growing Profit Margin: AFT's current net profit margins (8.9%) are higher than last year (2.8%).


Past Earnings Growth Analysis

Earnings Trend: AFT has become profitable over the past 5 years, growing earnings by 64% per year.

Accelerating Growth: AFT's earnings growth over the past year (256.7%) exceeds its 5-year average (64% per year).

Earnings vs Industry: AFT earnings growth over the past year (256.7%) exceeded the Pharmaceuticals industry 16.3%.


Return on Equity

High ROE: AFT's Return on Equity (26.4%) is considered high.


Financial Health

How is AFT Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AFT's short term assets (NZ$66.2M) exceed its short term liabilities (NZ$25.4M).

Long Term Liabilities: AFT's short term assets (NZ$66.2M) exceed its long term liabilities (NZ$39.2M).


Debt to Equity History and Analysis

Debt Level: AFT's net debt to equity ratio (79.3%) is considered high.

Reducing Debt: AFT's debt to equity ratio has reduced from 122.1% to 93.7% over the past 5 years.

Debt Coverage: AFT's debt is well covered by operating cash flow (26.8%).

Interest Coverage: AFT's interest payments on its debt are well covered by EBIT (4.8x coverage).


Balance Sheet


Dividend

What is AFT Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.61%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AFT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AFT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AFT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AFT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AFT's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.3yrs

Average board tenure


CEO

Hartley Atkinson

24.33yrs

Tenure

NZ$701,490

Compensation

Dr. Hartley Atkinson, M.Pharm (Dist), PhD, is Co-Founder of AFT Pharmaceuticals Limited in 1997. Dr. Atkinson is Chief Executive Officer of AFT Pharmaceuticals Limited since September 04, 1997 and also ser...


CEO Compensation Analysis

Compensation vs Market: Hartley's total compensation ($USD472.03K) is about average for companies of similar size in the NZ market ($USD545.58K).

Compensation vs Earnings: Hartley's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: AFT's board of directors are considered experienced (9.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AFT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AFT Pharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: AFT Pharmaceuticals Limited
  • Ticker: AFT
  • Exchange: NZSE
  • Founded: 1997
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NZ$436.588m
  • Shares outstanding: 104.70m
  • Website: https://www.aftpharm.com

Number of Employees


Location

  • AFT Pharmaceuticals Limited
  • 129 Hurstmere Road
  • Level 1
  • Auckland
  • 622
  • New Zealand

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/24 06:00
End of Day Share Price2022/01/24 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.